



Research Article

**CHROMATOGRAPHIC SEPARATION FOR CILAZAPRIL AND RELATED IMPURITIES
DETERMINATION**

M Sarat^a And C Rambabu^{a*}

^aAcharya Nagarjuna University, Nagarjuna nagar-522510, Guntur dist, Andhra Pradesh, India.

. (Received: 20 April 2013; Accepted: 23 April, 2013; Published: 30 June, 2013)

Corresponding Author's email: msarat_msc@yahoo.com

Abstract: A simple and rapid reverse-phase high-performance liquid chromatographic (HPLC) method for the simultaneous separation and determination of Cilazapril and its process-related impurities in bulk drugs has been developed. Four process-related impurities of Cilazapril have been separated on an Inertsil ODS-3V (C18) column and detected at 254 nm using a photo diode array (PDA). This HPLC method was successfully applied to the analysis of Cilazapril bulk drug. Recoveries of Cilazapril and process-related impurities were in the range of 92.86 – 106.23%, and found to be specific, precise and reliable for the determination of un-reacted raw materials, intermediates in the reaction mixtures and bulk drugs.

Keywords: Cilazapril, HPLC, process-related impurities

INTRODUCTION

Cilazapril is a novel drug which is being evaluated for the treatment of essential hypertension and congestive heart failure. Cilazapril is rapidly hydrolysed by non-specific esterases to the active acid metabolite cilazaprilat, which is a potent inhibitor of angiotensin converting enzyme (ACE). Cilazapril is a pyridazine angiotensin converting enzyme inhibitor (ACE inhibitor). Cilazapril works by causing blood vessels to relax. This lowers blood pressure by decreasing production of a strong chemical in the body. It helps the heart work more effectively. It improves blood flow and increases the supply of blood and oxygen to the heart. ACE inhibitors may be used for the treatment of several heart related problems & helps to decrease the risk of heart attacks. IC represents a universal analytical technique for the separation and quantitative determination of specific ion species. Complex mixtures of anions or cations can be separated to the level of specific ions and then quantified in a relatively short time. The main applications of IC methods are in the determination of trace anions in ultra pure water in the pharmaceutical industry, electronics, power plants, pulp and paper production.¹ The IC method can detect and quantify substances that cause color, smell and slime in the production process, as well as salts and other corrosive substances. These disturbing substances include volatile organic acids (acetic, formic, lactic and butyric) and inorganic salts present as anions: chloride, fluoride, sulfate, nitrate.²⁻⁹ A number of spectrophotometric methods were reported for the determination of Cilazapril in its binary mixtures.^{10, 11} And also HPLC methods for the specific determinations of Cilazapril along with other angiotensin-converting enzyme inhibitors is reported by^{12, 13} A validated method for the determination of Cilazapril and its metabolites in presence of other enzyme inhibitors are also reported¹⁴. Shalini Joshi reported a method for formulations by TLC, HPLC and RPTLC.¹⁵

EXPERIMENTAL

Reagents and chemicals

All reagents were of analytical grade unless stated otherwise. HPLC-grade water was provided by a Milli-Q® water purification system, Millipore Corp. (USA), HPLC-grade acetonitrile and ammonium acetate procured from Merck India Ltd. (India).

Apparatus

The HPLC system included two LC-10AT VP pumps, an SPD-M10A VP photo-diode array detector, a CTO-10AS VP oven and SCL-10A VP controller (all from Shimadzu, Japan). A reverse-phase Inertsil ODS-3V (GL Sciences Inc., Japan) column (25 cm × 4.6 mm i.d.; particle size, 5 µm) was used for separation, and chromatograms were integrated using Class software.

Chromatographic conditions

The mobile phase was 1% ammonium acetate and acetonitrile (55:45 v/v); before delivering into the column it was filtered through a 0.45 µm nylon filter and degassed. The analysis was carried out under isocratic condition using a flow rate of 1.0 ml/min at 30°C. Chromatograms were recorded at 254 nm using a PDA detector.

Analytical procedure

Solutions of (1000 µg/ml) Cilazapril and its process-related impurities were prepared by dissolving known amounts of components in a mobile phase. These solutions were further diluted to determine the accuracy, precision, linearity and limit of detection and limit of quantification.

RESULTS AND DISCUSSION

Optimization of chromatographic conditions

Figure 1 shows the synthetic process for the synthesis of Cilazapril. It can be seen from Fig. 1 that there

are four compounds that include the starting material and intermediates that could be present as a potential impurity in Cilazapril. The present study was aimed at developing a chromatographic system capable of eluting and separating Cilazapril and its synthetic impurities. All of the impurities and Cilazapril were subjected to separation by reverse-phase HPLC using different columns and mobile phases. The separation and peak shapes were good on Inertsil ODS-3V (4.6×250 mm, $5 \mu\text{m}$) column using 1% ammonium acetate and acetonitrile (55:45 v/v). A typical chromatogram of Cilazapril spiked with 25 ppm of each impurity is shown in Fig. 2. It is evident from Fig. 2 that all of the compounds were eluted and well separated with good peak shapes and resolutions. The UV wavelength at 254 nm was chosen for detection and quantification, since Cilazapril and its impurities have good absorption at that wavelength. The peaks were identified by injecting and comparing the retention times of individual compounds and studying the absorption spectra using a PDA detector (Fig. 3). The developed method was validated with respect to accuracy, precision, linearity and robustness.

Specificity

To demonstrate the specificity of the method, Cilazapril bulk drug was spiked with known amounts of impurities, and chromatographed. All of the impurities were well separated from Cilazapril; the chromatographic peak purity and the homogeneity were evaluated with a PDA detector. The peaks with a flat-top indicated that Cilazapril has a homogeneous peak with no impurities embedded in it. Also, the specificity was checked by stressing pure Cilazapril under UV light at 254 nm, and under extreme conditions, such as 0.1 N NaOH, 0.3 N HCl and 3% H_2O_2 at 60°C for 24 h. Under UV and acidic conditions there was no change in the purity, but in alkaline and oxidative conditions the degradation products were formed. However, they are well separated from Cilazapril and the process impurities, indicating that the method is specific for the separation and estimation of Cilazapril and its process impurities. It can be seen from the HPLC chromatogram of Cilazapril bulk drug (Fig. 4) that the process-related impurities were well separated from unknown impurities.

System suitability

The system suitability was evaluated by using 0.1% of all impurities spiked to Cilazapril (100 $\mu\text{g/ml}$), and evaluated by making five replicate injections. The system suitability parameters (retention time (t_r), relative retention time (RRT) and tailing factors) were evaluated, and are recorded in Table 1.

Linearity

The linearity of the detector response to different concentrations of impurities was studied by analyzing Cilazapril spiked with each impurity at seven levels ranging over 0.1 – 2.0 $\mu\text{g/ml}$; similarly, the linearity of Cilazapril was studied by preparing standard solutions at seven different levels, ranging over 25 – 300 $\mu\text{g/ml}$. The data were subjected to statistical analysis using linear-regression model. The correlation coefficients (R^2) for Cilazapril and its impurities were in the range of 0.995 – 0.999.

Accuracy and precision

The accuracy of the method for impurities was checked by spiking each impurity at three different concentration levels, ranging over 0.1 – 1.0 $\mu\text{g/ml}$ (0.1, 0.4 and 1.0 $\mu\text{g/ml}$) to the Cilazapril at a specified level (100 $\mu\text{g/ml}$). All estimations were made in triplicate ($n = 3$); the recoveries for all four impurities were found to be 92.86 – 106.23%. The precision of the method for impurities was tested by injecting six individual preparations of 100 $\mu\text{g/ml}$ of Cilazapril spiked with 0.1 $\mu\text{g/ml}$ of each impurity. The recoveries of each impurity were calculated, and the RSD was found to be in the range of 1.07 – 3.27%.

The accuracy and precision for determining the assay of Cilazapril was checked at three different levels: *i.e.*, 50, 100 and 200 $\mu\text{g/ml}$ each, in triplicate. Also, the RSD values were found to be below 1.0%. The intermediate precision is the inter-day variation at the same concentration levels determined on successive days. The inter-day variations calculated for three concentration levels are expressed in terms of %RSD, at each concentration level, the %RSD, values were below 1.5%, indicating a good intermediate precision.

Robustness

In order to evaluate the robustness of the method, the influence of a small and deliberate variation of the analytical parameter on Cilazapril and its impurities was studied. The robustness was studied by varying ± 0.2 ml of the flow rate, ± 2 ml of the acetonitrile composition in the mobile phase and $\pm 2^\circ\text{C}$ in the column temperature to the actual method parameters. In all of the above variations, test samples were injected in triplicate. There was a slight change in the retention times of Cilazapril and its impurities upon changing the mobile-phase concentration, but all peaks were well separated without affecting the accuracy of the quantitative estimation of Cilazapril and the impurities. There was no significant change observed upon changing the flow rate and the temperature. The result indicates that the method is suitable for the separation and estimation of Cilazapril and its synthetic impurities.

Limit of detection and quantification

The limit of detection (LOD) and quantification (LOQ) represent the concentrations of the analytes that would yield a signal-to-noise ratio of 3 for LOD and 10 for LOQ, respectively. LOD and LOQ were determined by measuring the magnitude of the analytical background by injecting blank samples and calculating the signal-to-noise ratio for each compound by injecting a series of solutions until the S/N ratio is 3 for LOD and 10 for LOQ. LOD and LOQ of all compounds lie in the range of 0.016 – 0.029 and 0.045 – 0.095 $\mu\text{g/ml}$, respectively.

Analysis of samples

First, accurately weigh 200 mg of a Cilazapril bulk drug sample into a 100-ml volumetric flask, and dissolve in the mobile phase and make up. This solution was used to estimate impurities. The impurities in bulk drug samples were identified by comparing the retention times and the UV spectral curves with that of standard impurities. The results are recorded in Table 2. Almost all impurities were found in

different quantities in all studied samples. Cilazapril -2 has the highest amount of impurity (0.14%), of which impurity D alone was 0.05%. The assay for determining Cilazapril when


carried out by diluting the above solution to 200 ppm with the mobile phase ranged from 99.67 to 99.80%.


Table 1. System suitability data

Compound	t_R /min	RRT	Tailing factor	λ_{max}/nm (ϵ)
A	6.75	0.45	1.26	231 (20889)
B	8.948	0.59	1.20	254 (15341)
C	11.904	0.79	1.08	252 (26380)
D	2.997	0.20	1.13	241 (57506)
Cilazapril	15.091	1.0	1.03	246 (42966)


Table 2. Results of analysis of bulk drugs

Sample	Impurities, % (w/w) \pm %RSD			
	A	B	C	D
Cilazapril - 1	-	0.01 \pm 1.03	-	0.03 \pm 0.82
Cilazapril - 2	0.03 \pm 3.53	0.04 \pm 2.44	0.01 \pm 2.87	0.05 \pm 2.87
Cilazapril - 3	0.03 \pm 1.10	0.02 \pm 1.21	0.02 \pm 0.23	0.03 \pm 1.37







Impurity - A



Impurity - B



Impurity - C



Impurity - D

Fig. 1. Chemical synthesis of Cilazapril and its related Impurities




Fig.2. Typical chromatogram of Cilazapril spiked with 25 ppm of each impurity (A, B, C and D)




Fig.3.Comparative UV absorption spectra of impurities (A, B, C and D) in standard and bulk drugs.




Fig.4. Typical chromatogram of a bulk drug (Uk, unknown impurity).

CONCLUSIONS

A simple reverse phase-HPLC method was developed and validated for the simultaneous estimation of Cilazapril and its process-related impurities in Cilazapril bulk drug. This method is selective, sensitive and precise for estimating Cilazapril and its process-related impurities, which may be present in trace levels in bulk drugs.

ACKNOWLEDGEMENTS

We thank to emmanthi laboratories limited, Hyderabad, India, for his encouragement and support.

REFERENCES

1. Cickaric D, Dersek-Timotic I, Onjia A, Rajakovic LJJ. *Serb. Chem. Soc.*, **2005**; 70: 995.
2. Zarkovic Darja, Todorovic Saklina Krgovic Milorad and Rajakovic Ijubinka, J. *Serb. Chem. Soc.*, **2009**; 74(3): 301-310.
3. Lane Edmund, Alexis, Holden j and Coward Robert A, *The Analyst*, **1994**; 124: 245-249.
4. Yan-zhen, ZHANG.; Zheng-yi, ZHANG ZHOU.; Yan-chun, ZHANG.; liu li, ZHU.; Yan, Zhang j Zhejiang, *Univ Sci*, **2007**; 8(5): 302- 306.
5. Michalski, R. *Polish Journal of Environmental Studies*, **2004**; 13: 73-77.
6. Liang-Yen Lin and Shiuh-jen Jiang, *Journal of the Chinese Chemical Society*, **2009**; 56: 967-973.
7. Girish R. Deshpande, Rao B.M, and Someswara Rao, *Rasayan J. Chem.*, **2009**; 2: 101-107.
8. Girish R. Deshpande, Rao B.M, Rama sowjanya T and Someswara Rao, *Rasayan J. Chem.*, **2009**; 2: 87-95.
9. Margaret Neal, Colin Neal, Heather Wickham and Sarah Harman, *Hydrol, Earth Syst. Sci.* **2007**; 11(1): 294-300.
10. Erk, N. Onur. F.; *Analytical letters*, **1996**; 29: 11.
11. Dinc, E.; Baleanu, D.; *J Pharm Biomed Anal*, **2002**; 15: 30(3): 715-23.
12. Gumieniczeka, A.; Przyborowski, L.; *Journal of Liquid Chromatography & Related Technologies*, **2007**; 20: 2135-2142.
13. Okan Atay U. ur Tamer, Dilek Arikan, *Analytical letters*, **2006**; 34(7): 1153-1161.
14. Zorica Vujic, Milkica Crevar, Vladimir Obradovic, Vesna Kuntic, Snezana Uskavic, Markovic, *Chromatographia*, **2009**; 70: 1221-1225 (2009).
15. Shalini Joshi, Amrita Sharma, MS Rawat, CS Bal, *Asian journal of pharmaceuticals*, **2009**.